Trial Information

Summary: Peripheral Blood Stem Cell Mobilization and Storage in Patients with Chronic Myelogenous Leukemia in Complete Cytogenetic Remission on Imatinib.

This is a study to see the safety and feasibility of harvesting peripheral blood stem cells from patients with CML in complete cytogenetic remission on Imatiinib. Peripheral blood stem cells in remission can be collected, frozen and stored for future use for autologous transplantation, should the CML become resistant to Imatinib, or show signs of acceleration. Imatinib will be temporarily discontinued. Filgrastim (G-CSF) will be given to stimulate stem cells, and an apheresis catheter inserted. Up to five days of pheresis will be undertaken to get adequate numbers of stem cells. Percentage of Philadelphia chromosome will be checked pre- and post-harvest. After harvesting patients will resume Imatinib and return to the care of their primary oncologist.

Study Criteria:

• CML in complete cytogenetic remission as measured by bone marrow evaluation within 1 month.
• On Imatinib greater than 3 months.
• Age >18.
• Adequate organ function for transplantation.
• HIV negative.
• Patients must either not be eligible or currently refusing allogeneic stem cell transplantation.
• Marrow myelofibrosis < 3+.

For more information,

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 5:44:56 AM